Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Venrock Healthcare Capital Par Acquires 88,794 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average price of $11.44 per share, for a total transaction of $1,015,803.36. Following the completion of the transaction, the insider now directly owns 4,148,428 shares of the company’s stock, valued at $47,458,016.32. The trade was a 2.19 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, February 12th, Venrock Healthcare Capital Par bought 8,971 shares of Oruka Therapeutics stock. The stock was acquired at an average cost of $11.86 per share, for a total transaction of $106,396.06.
• On Monday, February 10th, Venrock Healthcare Capital Par purchased 574 shares of Oruka Therapeutics stock. The stock was bought at an average price of $10.90 per share, with a total value of $6,256.60.

Oruka Therapeutics Trading Down 9.2 %

NASDAQ ORKA opened at $9.56 on Friday. The business’s fifty day simple moving average is $14.49. The stock has a market cap of $334.59 million, a PE ratio of -1.53 and a beta of 0.77. Oruka Therapeutics, Inc. has a twelve month low of $9.53 and a twelve month high of $53.88.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ORKA. FMR LLC raised its stake in shares of Oruka Therapeutics by 17.7% in the 4th quarter. FMR LLC now owns 5,512,300 shares of the company’s stock valued at $106,883,000 after acquiring an additional 830,000 shares during the period. Fairmount Funds Management LLC increased its holdings in Oruka Therapeutics by 5.0% in the 4th quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company’s stock valued at $65,382,000 after purchasing an additional 160,000 shares during the last quarter. VR Adviser LLC raised its position in Oruka Therapeutics by 6.5% in the fourth quarter. VR Adviser LLC now owns 3,285,620 shares of the company’s stock valued at $63,708,000 after purchasing an additional 200,000 shares during the period. RTW Investments LP lifted its stake in Oruka Therapeutics by 5.1% during the fourth quarter. RTW Investments LP now owns 1,945,649 shares of the company’s stock worth $37,726,000 after purchasing an additional 95,001 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Oruka Therapeutics by 4,161.2% during the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock worth $31,231,000 after buying an additional 1,572,853 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on ORKA shares. Wolfe Research initiated coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, February 7th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.